18F-FDG Avidity in Lymphoma Readdressed: A Study of 766 Patients

PET/CT with 18F-FDG is an important noninvasive diagnostic tool for management of patients with lymphoma, and its use may surpass current guideline recommendations. The aim of the present study is to enlarge the growing body of evidence concerning 18F-FDG avidity of lymphoma to provide a basis for future guidelines. Methods: The reports from 18F-FDG PET/CT studies performed in a single center for staging of 1,093 patients with newly diagnosed Hodgkin disease and non-Hodgkin lymphoma between 2001 and 2008 were reviewed for the presence of 18F-FDG avidity. Of these patients, 766 patients with a histopathologic diagnosis verified according to the World Health Organization classification were included in the final analysis. 18F-FDG avidity was defined as the presence of at least 1 focus of 18F-FDG uptake reported as a disease site. Nonavidity was defined as disease proven by clinical examination, conventional imaging modalities, and histopathology with no 18F-FDG uptake in any of the involved sites. Results: At least one 18F-FDG–avid lymphoma site was reported for 718 patient studies (94%). Forty-eight patients (6%) had lymphoma not avid for 18F-FDG. 18F-FDG avidity was found in all patients (100%) with Hodgkin disease (n = 233), Burkitt lymphoma (n = 18), mantle cell lymphoma (n = 14), nodal marginal zone lymphoma (n = 8), and lymphoblastic lymphoma (n = 6). An 18F-FDG avidity of 97% was found in patients with diffuse large B-cell lymphoma (216/222), 95% for follicular lymphoma (133/140), 85% for T-cell lymphoma (34/40), 83% for small lymphocytic lymphoma (24/29), and 55% for extranodal marginal zone lymphoma (29/53). Conclusion: The present study indicated that with the exception of extranodal marginal zone lymphoma and small lymphocytic lymphoma, most lymphoma subtypes have high 18F-FDG avidity. The cumulating evidence consistently showing high 18F-FDG avidity in the potentially curable Burkitt, natural killer/T-cell, and anaplastic large T-cell lymphoma subtypes justifies further investigations of the utility of 18F-FDG PET in these diseases at presentation.

[1]  Heinrich R Schelbert,et al.  Improvements in cancer staging with PET/CT: literature-based evidence as of September 2006. , 2007, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[2]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[3]  Sigrid Stroobants,et al.  Revised response criteria for malignant lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  S. de Vos,et al.  The impact of fluorodeoxyglucose-positron emission tomography in primary staging and patient management in lymphoma patients. , 2008, Radiologic clinics of North America.

[5]  J. Armitage,et al.  F-18-fluoro-deoxy-glucose positron emission tomography in the assessment of peripheral T-cell lymphomas , 2007, Leukemia & lymphoma.

[6]  V. Ambrosini,et al.  18F-FDG PET in mucosa-associated lymphoid tissue (MALT) lymphoma , 2006, Leukemia & lymphoma.

[7]  D. Fischer,et al.  FDG avidity and PET/CT patterns in primary gastric lymphoma , 2008, European Journal of Nuclear Medicine and Molecular Imaging.

[8]  R. Coleman,et al.  NCCN Task Force Report : Positron Emission Tomography ( PET ) / Computed Tomography ( CT ) Scanning in Cancer , 2007 .

[9]  J. V. van Waesberghe,et al.  18F-FDG PET versus CT for the detection of enteropathy-associated T-cell lymphoma in refractory celiac disease. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[10]  A. Levis,et al.  Positron emission tomography in the staging of patients with Hodgkin’s lymphoma. A prospective multicentric study by the Intergruppo Italiano Linfomi , 2007, Annals of Hematology.

[11]  A. Chott,et al.  18F-fluoro-deoxy-glucose positron emission tomography (18F-FDG-PET) for assessment of enteropathy-type T cell lymphoma , 2003, Gut.

[12]  K. Beal,et al.  FDG-PET scanning for detection and staging of extranodal marginal zone lymphomas of the MALT type: a report of 42 cases. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[13]  R. Hustinx,et al.  Positron emission tomography (PET) with 18F-fluorodeoxyglucose (18F-FDG) for the staging of low-grade non-Hodgkin's lymphoma (NHL). , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[14]  O. Bairey,et al.  Diagnostic accuracy of PET/CT in patients with extranodal marginal zone MALT lymphoma , 2007, European journal of haematology.

[15]  A. Zelenetz,et al.  Overview of lymphoma diagnosis and management. , 2008, Radiologic clinics of North America.

[16]  Emmanuel Itti,et al.  Early 18F-FDG PET for Prediction of Prognosis in Patients with Diffuse Large B-Cell Lymphoma: SUV-Based Assessment Versus Visual Analysis , 2007, Journal of Nuclear Medicine.

[17]  A. Jemal,et al.  Cancer Statistics, 2008 , 2008, CA: a cancer journal for clinicians.

[18]  U. Jäger,et al.  F-Fluorodeoxyglucose Positron Emission Tomography ( 18 F-FDG-PET ) for Staging and Follow-Up of Marginal Zone B-Cell Lymphoma , 2003 .

[19]  K. Ohtomo,et al.  FDG-PET in T-cell and NK-cell neoplasms. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

[20]  M. Kojima,et al.  The usefulness of (18)F-fluorodeoxyglucose positron emission tomography ((18)F-FDG-PET) and a comparison of (18)F-FDG-pet with (67)gallium scintigraphy in the evaluation of lymphoma: relation to histologic subtypes based on the World Health Organization classification. , 2007, Cancer.

[21]  T. Nazeer,et al.  Role of fluorine‐18 fluoro‐deoxyglucose positron emission tomography scan in the evaluation and follow‐up of patients with low‐grade lymphomas , 2006, Cancer.

[22]  R. Hicks,et al.  [18F]fluorodeoxyglucose positron emission tomography scanning for staging, response assessment, and disease surveillance in patients with mantle cell lymphoma. , 2008, Clinical lymphoma & myeloma.

[23]  A. Alavi,et al.  Utility of FDG-PET scanning in lymphoma by WHO classification. , 2003, Blood.

[24]  A. Alavi,et al.  F-fluorodeoxyglucose–positron emission tomography in evaluation of primary cutaneous lymphoma , 2006 .

[25]  M. Blaufox,et al.  A metaanalysis of 18F‐2‐deoxy‐2‐fluoro‐D‐glucose positron emission tomography in the staging and restaging of patients with lymphoma , 2005, Cancer.